Meyka Pro banner
Formycon AG

Formycon AG Fundamental Analysis (XETRA: FYB.DE)

FYB.DE●XETRA
HealthcareBiotechnology
€18.84
€0.14(0.74%)
German Market opens in 21h 0m

Formycon AG Fundamental Analysis (XETRA: FYB.DE)

Formycon AG (XETRA: FYB.DE) shows weak financial fundamentals with a PE ratio of -13.27, profit margin of -41.04%, and ROE of -6.41%. The company generates $0.1B in annual revenue with weak year-over-year growth of -36.17%.

Key Strengths

Cash Position15.55%
PEG Ratio-0.08
Current Ratio2.04

Areas of Concern

ROE-6.41%
Operating Margin-25.51%
We analyze FYB.DE's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -44.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-44.0/100

We analyze FYB.DE's fundamental strength across five key dimensions:

Efficiency Score

Weak

FYB.DE struggles to generate sufficient returns from assets.

ROA > 10%
-3.52%

Valuation Score

Excellent

FYB.DE trades at attractive valuation levels.

PE < 25
-13.27
PEG Ratio < 2
-0.08

Growth Score

Moderate

FYB.DE shows steady but slowing expansion.

Revenue Growth > 5%
-36.17%
EPS Growth > 10%
49.03%

Financial Health Score

Excellent

FYB.DE maintains a strong and stable balance sheet.

Debt/Equity < 1
0.02
Current Ratio > 1
2.04

Profitability Score

Weak

FYB.DE struggles to sustain strong margins.

ROE > 15%
-640.55%
Net Margin ≥ 15%
-41.04%
Positive Free Cash Flow
No

Key Financial Metrics

Is FYB.DE Expensive or Cheap?

P/E Ratio

FYB.DE trades at -13.27 times earnings. This suggests potential undervaluation.

-13.27

PEG Ratio

When adjusting for growth, FYB.DE's PEG of -0.08 indicates potential undervaluation.

-0.08

Price to Book

The market values Formycon AG at 0.86 times its book value. This may indicate undervaluation.

0.86

EV/EBITDA

Enterprise value stands at 36.88 times EBITDA. This signals the market has high growth expectations.

36.88

How Well Does FYB.DE Make Money?

Net Profit Margin

For every $100 in sales, Formycon AG keeps $-41.04 as profit after all expenses.

-41.04%

Operating Margin

Core operations generate -25.51 in profit for every $100 in revenue, before interest and taxes.

-25.51%

ROE

Management delivers $-6.41 in profit for every $100 of shareholder equity.

-6.41%

ROA

Formycon AG generates $-3.52 in profit for every $100 in assets, demonstrating efficient asset deployment.

-3.52%

Following the Money - Real Cash Generation

Operating Cash Flow

Formycon AG generates limited operating cash flow of $-4.88M, signaling weaker underlying cash strength.

$-4.88M

Free Cash Flow

Formycon AG generates weak or negative free cash flow of $-5.62M, restricting financial flexibility.

$-5.62M

FCF Per Share

Each share generates $-0.32 in free cash annually.

$-0.32

FCF Yield

FYB.DE converts -1.69% of its market value into free cash.

-1.69%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-13.27

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.08

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.86

vs 25 benchmark

P/S Ratio

Price to sales ratio

5.44

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.02

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.04

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.06

vs 25 benchmark

ROA

Return on assets percentage

-0.04

vs 25 benchmark

ROCE

Return on capital employed

-0.02

vs 25 benchmark

How FYB.DE Stacks Against Its Sector Peers

MetricFYB.DE ValueSector AveragePerformance
P/E Ratio-13.2731.29 Better (Cheaper)
ROE-6.41%543.00% Weak
Net Margin-41.04%8965.00% Weak
Debt/Equity0.020.51 Strong (Low Leverage)
Current Ratio2.045.79 Strong Liquidity
ROA-3.52%-96.00% (disorted) Weak

FYB.DE outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Formycon AG's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-19.09%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-498.63%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

228.91%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ